MD, PhD, Movement Disorders Specialist,
Investigator, Scientist
Investigator, Scientist
specialized in the field of neurodegenerations
About me
My name is Diana Khasanova. And I am a passionate neurologist specializing in movement disorders, with a strong commitment to advancing both medical care and digital technologies in healthcare.
I work as a Neurologist at the Consultative and Diagnostic Center for Movement Disorders and Botulinum Therapy in the Republic of Tatarstan and as Associate Professor in Kazan State Medical University at Digital Technologies in Healthcare Dept.
In recent years, I have embarked on an exciting journey focused on innovative solutions in neurodegeneration diagnostics, aiming to drive a significant shift in public healthcare. My work is rooted in the understanding that as our population ages, the challenges associated with neurodegenerative diseases—such as Alzheimer's, Parkinson's, and other cognitive disorders—become increasingly pressing.
I'm enthusiastic about integrating information technology into medicine. I recognize the transformative potential of digital tools and data analytics in enhancing patient care, streamlining processes, and improving health outcomes.
My vision is to contribute to a healthcare system that is proactive rather than reactive, particularly concerning neurodegenerative diseases. By fostering collaboration between technology developers, healthcare providers, and researchers, we can create a robust ecosystem that prioritizes early diagnosis and effective management of these conditions. The goal is to empower individuals and communities to navigate the challenges of aging with confidence and support.
My main project today is BRAINPHONE - ARTIFICIAL INTELLIGENCE TECHNOLOGIES FOR BRAIN DISORDERS DETECTION VIA VOICE AND SPEECH
I work as a Neurologist at the Consultative and Diagnostic Center for Movement Disorders and Botulinum Therapy in the Republic of Tatarstan and as Associate Professor in Kazan State Medical University at Digital Technologies in Healthcare Dept.
In recent years, I have embarked on an exciting journey focused on innovative solutions in neurodegeneration diagnostics, aiming to drive a significant shift in public healthcare. My work is rooted in the understanding that as our population ages, the challenges associated with neurodegenerative diseases—such as Alzheimer's, Parkinson's, and other cognitive disorders—become increasingly pressing.
I'm enthusiastic about integrating information technology into medicine. I recognize the transformative potential of digital tools and data analytics in enhancing patient care, streamlining processes, and improving health outcomes.
My vision is to contribute to a healthcare system that is proactive rather than reactive, particularly concerning neurodegenerative diseases. By fostering collaboration between technology developers, healthcare providers, and researchers, we can create a robust ecosystem that prioritizes early diagnosis and effective management of these conditions. The goal is to empower individuals and communities to navigate the challenges of aging with confidence and support.
My main project today is BRAINPHONE - ARTIFICIAL INTELLIGENCE TECHNOLOGIES FOR BRAIN DISORDERS DETECTION VIA VOICE AND SPEECH
Education
1
2004-2010
Kazan State Medical University
Kazan State Medical University
Physician,
Diploma BCA №0974584
Diploma BCA №0974584
2
2005-2009
Kazan State Technological University
Kazan State Technological University
Interpreter in sphere of professional communications
Diploma PPK 131500
Diploma PPK 131500
3
2010-2011
Internship, Kazan State Medical University
Internship, Kazan State Medical University
Neurologist
Certificate A No.4214527 issued on 05 Jul 2011
Certificate A No.4214527 issued on 05 Jul 2011
4
2011-2015
Kazan State Medical University
Kazan State Medical University
Postgraduate Fellow
5
2012 - 2017
PhD dissertation “Clinical presentation and catecholamines’ metabolism in diagnostics of early stages of Parkinson Disease”
PhD dissertation “Clinical presentation and catecholamines’ metabolism in diagnostics of early stages of Parkinson Disease”
6
2023
Supplementary professional education Private Institution “Educational organization of additional professional education "International Academy of Expertise and Assessment"
Supplementary professional education Private Institution “Educational organization of additional professional education "International Academy of Expertise and Assessment"
Statistics
Certificate No. 2023/235-6832 issued on 20 Mar 2023
Certificate No. 2023/235-6832 issued on 20 Mar 2023
7
2023
Supplementary professional education Autonomous non-profit organization of additional professional Education "Sberbank Corporate University"
Supplementary professional education Autonomous non-profit organization of additional professional Education "Sberbank Corporate University"
Data analysis
Certificate No. PK 216207 issued on 31 Oct 2023
Certificate No. PK 216207 issued on 31 Oct 2023
My Researcher's expertise
I have been involved in research activities since my high school years, and I have also actively participated in projects during my university studies.
Clinical trials
- A Phase III, randomised, double blind and open label phase, active and placebo controlled study comparing the short term efficacy of two formulations of clostridium botulinum type A toxin (Dysport and Dysport RU) to placebo, and assessing the short and long term efficacy and safety of Dysport RU following repeated treatments of subjects with cervical dystonia (CD) (2012-2014)Co-investigator
- Protocol S187.3.004, S187.3.005: An Open-Label, 12 Months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson’s Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson’s Disease Medications (2014-2020)Co-investigator
- REGISTRY – multicenter, multinational, prospective, observational study on Huntington's disease, including a control group volunteers (2014 – 2018)Coordinator, Co-Investigator
- TV7820-CNS-20002 A randomized, double-blind, placebo-controlled, phase 2 study conducted in parallel groups to determine the dosage, assess safety and efficacy of pridopidine taken at doses of 45 mg, 67.5 mg, 90 mg, and 112.5 mg twice daily, with placebo for symptomatic treatment of patients with Huntington's disease (2014 - 2016)Co-investigator
- TV7820-CNS-20016 A multicentre, open-label study to assess the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (an open PRIDE-HD trial) (Open Study for Estimating the Dose of Pridopidine in the Treatment of Huntington's Disease) (2016 – 2018)Co-investigator
- TV5600-CNS-20007 Protocol of clinical research as amended 04 An international multicenter, randomized, double-blind, placebo-controlled study conducted in parallel groups to assess the efficacy and safety of the laquinimod (0.5, 1.0 and 1.5 mg / day) for the treatment of patients with Huntington's disease (2016 - 2018)Co-investigator
- BN40423 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study To Evaluate The Efficacy And Safety Of Intrathecally Administered Ro7234292 (Rg6042) In Patients With Manifest Huntington's Disease (2019 – 2022)Co-investigator
- ND0612-317A multicenter, randomized, active drug-controlled, double-blind, double-blind, parallel group clinical trial to investigate the efficacy, safety and tolerability of continuous subcutaneous infusion of ND0612 versus oral IR-LD / CD in patients with Parkinson's disease, with motor fluctuations (BouNDless) (2022-2023)Co-investigator
- SN-SPAS-202, entitled “A Phase 2/3, Multicenter, Randomized, Double-Blind, Single-Treatment Efficacy and Safety Study of MYOBLOC in the Treatment of Adult Lower Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC” (2022 – 2023)Coordinator, Co-investigator
- SN-SPAS-201, entitled “A Phase 2/3, Multicenter, Randomized, Double-Blind, Single-Treatment Efficacy and Safety Study of MYOBLOC in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC” (2022 – 2023)Coordinator, Co-investigator
GRANTS
2010-2013
Research and development work in priority areas of science and technology development" within the framework of the "START-2011" program with the project "A method for diagnostics of the preclinical stage of Parkinson's disease"
Role: Investigator
2023-2024
Research and development work in priority areas of science and technology development" within the framework of the "START-1" program with the project "Artificial intelligence-based voice diagnostics and monitoring service for Parkinson's disease" (BRAINPHONE project)
Budget - ₽4 mln
Funded by the Fundation for Assistance to Small Innovative Enterprises (FASIE).
Funded by the Fundation for Assistance to Small Innovative Enterprises (FASIE).
Role: Head, Investigator
2024
Database formulation within the project "Artificial intelligence-based voice diagnostics and monitoring service for Parkinson's disease" (BRAINPHONE project)
Budget - ₽1.5 mln
Funded by Skolkovo
Funded by Skolkovo
Role: Head, Investigator
2024-2025
Development and commercialization work with the project "Artificial intelligence-based voice diagnostics and monitoring service for Parkinson's disease" (BRAINPHONE project)
Budget - ₽7 mln
Funded by Skolkovo
Funded by Skolkovo
Role: Investigator
Work experience
1
2008 - 2016
Freelance interpreter
2
2011 - till now
Clinical researcher
- within Kazan State Medical University
3
2011 – till now
Neurologist (Movement Disorders Specialist)
- in Republican Consultative and Diagnostic Centre for Movement Disorders and Botulinum Therapy
4
2018 - 2021
Medical Writer / Medical Expert
- LLC StatAnDocs
5
2023-till now
Director
- BRAINPHONE LLC (Digital solutions for diagnosing and monitoring neurodegenerative diseases)
6
2024-till now
Associate Professor
- Kazan State Medical University, Digital Technologies in Healthcare Dept.
My expertise
Membership in organizations
AI Alliance
(Healthcare group)
(Healthcare group)
The Alliance is an informal voluntary network and community for its esteemed Members to exchange views, share information and expertise, and enhance cooperation in the field of artificial intelligence
Learn more
International Parkinson’s Disease and Movement Disorders Society (MDS)
More than 11,000 clinicians, scientists and other healthcare professionals dedicated to improving care for some of the most challenging disorders through education and research.
Learn more
HealthAI
The Global Agency for responsible AI in Health
The Global Agency for responsible AI in Health
HealthAI is a nonprofit organization focused on expanding countries' capacity to regulate artificial intelligence in health.
Learn more
Study groups participation
Technology Study Group (member)
International Parkinson’s Disease and Movement Disorders Society
The Technology Study Group will act as an engine for brainstorming about research collaborations in technology, and seek to act as an incubator for innovative technology ideas and collaborations within MDS.
Ethics Group
(member)
(member)
AI Alliance
The duties of the ethics group within the AI Alliance are crucial for promoting responsible and ethical practices in artificial intelligence development. The ethics group aims to foster an environment where AI is developed responsibly, addressing societal needs while mitigating potential risks associated with its deployment.
Voice, Speech, and Swallowing Study Group (member)
International Parkinson’s Disease and Movement Disorders Society
This international and multidisciplinary group aims to share clinical and research experience across the world in all aspects of communication and swallowing difficulties of patients with Movement disorders.
Publications (chosen)
Practical medicine, 2024
International Conference on Alzheimer's and Parkinson's diseases and related neurological disorders (ADPD 2024)
2024 International Congress
2024 International Congress
MDS Virtual Congress 2021
Current Metabolomics, 2018
Annals of Clinical and Experimental Neurology. 2024
2018 International Congress
Practical medicine, 2024
Zhurnal nevrologii i psikhiatrii im S S Korsakova, 2023
Parkinsonism & Related Disorders, 2018
Feel free to contact me
Diana Khasanova
MD, PhD, Movement Disorders Specialist, IT-enthusiast
[email protected]
Telegram: https://t.me/diana_khasanova
Telegram: https://t.me/diana_khasanova
